Biodistribution and antitumoral effect of long-circulating and pH-sensitive liposomal cisplatin administered in Ehrlich tumor-bearing mice

Experimental Biology and Medicine

Volumn 236, Issue 7, 2011, Pages 808-815

  Araújo, José Geraldo Coimbra ^a   das Graças Mota, Luciene ^a   Leite, Elaine Amaral ^a,b   de Carvalho Maroni, Laís ^c   Wainstein, Alberto Julius Alves ^a   Coelho, Luiz Gonzaga Vaz ^a   Savassi Rocha, Paulo Roberto ^a   Pereira, Márcio Tadeu ^d   de Carvalho, Andréa Teixeira ^c   Cardoso, Valbert Nascimento ^a   de Oliveira, Mônica Cristina ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSIDADE FEDERAL DOS VALES DO JEQUITINHONHA E MUCURI   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d CENTRO DE DESENVOLVIMENTO DA TECNOLOGIA NUCLEAR   (Brazil)

Author keywords

Antitumoral effect; Biodistribution; Cancer; Cisplatin; Liposomes; Pharmacokinetics

Indexed keywords

CISPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASCITES FLUID; ATAXIA; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; DRUG UPTAKE; EHRLICH ASCITES TUMOR; FEMALE; KIDNEY; LIVER; LOADING DRUG DOSE; LUNG; MOUSE; NONHUMAN; PERITONEAL CAVITY; PH; REFLEX; SINGLE DRUG DOSE; SPLEEN; SURVIVAL RATE; WEAKNESS;

ANIMAL STRUCTURES; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, EHRLICH TUMOR; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG CARRIERS; HUMANS; HYDROGEN-ION CONCENTRATION; LIPOSOMES; MICE; PERITONEAL NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

MUS;

EID: 79960676742     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2011.011038     Document Type: Article

References (16)

1. Fujiyama J, Nakase Y, Osaki K, Sakakura C, Yamagishi H, Hagiwar A. Cisplatin incorporated in microspheres: development and fundamental studies for its clinical application. J Control Release 2003;89:397-408
2. Tamura T, Imai J, Matsumoto A, Tanimoto M, Suzuki A, Horikiri Y, Suzuki T, Yoshino H, Ike O. Organ distribution of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres. Eur J Pharm Biopharm 2002;54:1-7
3. Gerber SA, Rybalko VY, Bigelow CE, Lugade AA, Foster TH, Frelinger JG, Lord EM. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol 2006;169:1739-1752
4. Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PN, Chevrette M, Provencher DM, Mes-Masson AM. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 2007;9:820-829
5. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burguer RA. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43
6. Rossi CR, Mocellin S, Pilati P, Foletto M, Quintieri L, Palatini P, Lise M. Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg Oncol Clin N Am 2003;12:781-794
7. Chauffert B, Favoulet P, Polycarpe E, Duvillard C, Beltramo JL, Bichat F, Rat P, Genne P, Benoit L. Rationale supporting the use of vasoconstrictors for intraperitoneal chemotherapy with platinum derivatives. Surg Oncol Clin N Am 2003;12:835-848
8. Tamura T, Imai J, Tanimoto M, Matsumoto A, Suzuki A, Horikiri Y, Suzuki T, Yoshino H. Relation between dissolution profiles and toxicity of cisplatin-loaded microspheres. Eur J Pharm Biopharm 2002;53:241-247
9. Leite EA, Giuberti CS, Wainstein AJ, Wainstein AP, Coelho LG, Lana AM, Savassi-Rocha PR, De Oliveira MC. Acute toxicity of long-circulating and pH-sensitive liposomes containing cisplatin in mice after intraperitoneal administration. Life Sci 2009;8:641-49
10. Leal AS, Carvalho-Ju ́nior AD, Abrantes FM, Menezes MA, Ferraz V, Cruz TS, Cardoso VN, De Oliveira MC. Production of the radioactive antitumoral cisplatin. Appl Radiat Isot 2006;64:178-181
11. Júnior ADC, Mota LG, Nunan EA, Wainstein AJ, Wainstein AP, Leal AS, Cardoso VN, De Oliveira MC. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor bearing mice. Life Sci 2007;80:659-664
12. Chen LC, Chang CH, Yu CY, Chang YJ, Hsu WC, Ho CL, Yeh CH, Luo TY, Lee TW, Ting G. Biodistribution, pharmacokinetics and imaging of 188Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol 2007;34:415-423
13. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005;5:161-171
14. Los G, Mustaers PH, Lenglet WJ, Baldew GS, McVie JG. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 1990;25:389-394
15. Vadiei K, Siddik ZH, Khokhar AR, al-Baker S, Sampedro F, Perez-Soler R. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) and cisplatn given i.v. and i.p. in the rat. Cancer Chemother Pharmacol 1992;30:365-369
16. Phillips WT, Medina LA, Klipper R, Goins B. A novel approach for the increased delivery of pharmaceutical agents to peritoneum and associated lymph nodes. J Pharmacol Exp Ther 2002;303:11-16